Senti Biosciences presented positive preliminary data from its Phase 1 trial of SENTI-202, showing 5 of 7 evaluable patients with relapsed/refractory AML achieved objective responses, including 4 complete remissions that were all MRD-negative.
Senti Bio has announced an additional $11.5 million in financing, extending its cash runway into 2026, supporting the advancement of its Gene Circuit platform.